Acorda Therapeutics Gets Crushed After Halting Parkinson’s Trial
Acorda Therapeutics saw its shares drop sharply following an announcement that it had paused new enrollment in a long-term safety study. In a sense, Acorda has halted this trial.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 152
Loxo Loses Out Despite Signing Big Cancer Deal
Loxo Oncology has announced that it will be partnering with Bayer to develop and commercialize larotrectinib and LOXO-195. Investors seem to believe that Loxo would have been better on its own. At least that’s…
Why Argus Is Taking a Step Back on Gilead Sciences
Gilead Sciences, Inc. (NASDAQ: GILD) saw its shares take a step back on Monday after an independent research firm downgraded the stock. Many investors have been hoping that the shares will pull out of…
Short Sellers Back Way Off Major Pharma
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
3 Companies Spearheading the Antibiotics Space in 2018
Thanks to progress made in 2017 though, it looks like 2018 could see both a radically new way of delivering antibiotics and finally the first new class approved in 30 years. Here are three…
Short Sellers Grow More Selective on Major Biotechs
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Biosimilars Have Massive Sales Potential: 5 Top Drug Stocks to Buy Now
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
Sage Therapeutics Wins Big in Depression Trial
Sage Therapeutics shares absolutely exploded on Thursday after the firm announced top-line results from its late-stage trial in severe postpartum depression.
Why Otonomy Shares Are Skyrocketing
Otonomy reported its most recent quarterly results after the markets closed on Wednesday and gave an update on its late-stage trial in patients with Ménière’s disease.
Voyager Therapeutics Gears Up for Secondary Offering
Voyager Therapeutics has seen a decent year for its shares and it seems now is the best time to cash in with a secondary offering.
Keryx Biopharmaceuticals FDA Win Outweighed by Q3 Loss
Keryx Biopharmaceuticals shares took a hit on Tuesday after the company announced its third-quarter results and an update from the FDA.
Valeant Earnings Soar on Tax Benefit
Drug maker Valeant got a big profit boost from a one-time tax benefit and the company also boosted its EPS guidance and trimmed its revenue guidance for the full year.
Why Solid CVS Health Earnings Are Not Enough
CVS Health reported solid third-quarter financial results before the markets opened on Monday, but that was not enough for investors.
Why Mylan Shares Were Bouncing Around After Q3 Earnings
Pharmaceutical maker Mylan missed analysts' consensus estimate for earnings and revenue. Additional guidance is mixed, causing shares first to fall then to rise. Which direction is more appropriate?
Sarepta Takes Another Big Step Forward With DMD Treatment
Sarepta Therapeutics saw its shares hit a new multiyear high on Friday after the firm announced that it received a key approval from the FDA.